Apply Now for Aquinox Pharmaceutical Jobs
Aquinox clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. Our primary focus is anti-inflammatory product candidates targeting SH2-containing inositol-5′-phosphatase 1, or SHIP1, which is a key regulator of an important cellular signaling pathway in immune cells, known as the PI3K pathway.
Aquinox Pharmaceuticals, Inc. commenced operations in 2006 as a spin-off from the University of British Columbia, the BC Cancer Agency and the Vancouver Coastal Health Research Institute, all organizations with outstanding reputations for world-class research. Our Collaborations with & Partner agencies are British Columbia Cancer Agency & University of British Columbia.
We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Aquinox Pharmaceutical Inc’s financial performance into perspective.
Our employees work with commitment and diligence to ensure that our objectives are delivered on time and with top quality. Our employees take action to solve problems, involve others as required, and often work beyond the scope of their role. Our employees share information in an effective and timely manner, and engage in healthy debates with their colleagues.